Skip to main content
Premium Trial:

Request an Annual Quote

EGeen, Prediction Sciences In Second Pharmacogenetics Collaboration

NEW YORK, Jan. 13-EGeen International and Prediction Sciences will collaborate to study the pharmacogenetics of Paxil, the two companies said today.

 

EGeen will provide the clinical data and Prediction Sciences will supply bioinformatics expertise to determine the genetic basis of patient response to this commonly prescribed anti-depressant.

 

EGeen, based in Redwood City, Calif., has exclusive commercial rights to data from the Estonian Gene Bank, a national database collecting genetic and clinical information from patients throughout Estonia. The company uses this database for drug and diagnostic discovery and for pharmacogenomic studies.

 

Prediction Sciences is a San Diego, Calif.-based private company developing bioinformatics for pharmacogenetic applications.

 

Earlier this year, the two companies struck a similar partnershipto study the pharmacogenetics of Celexa, another treatment for depression. Prediction Sciences hopes to create a comprehensive pharmacogenetic diagnostic panel to guide in the prescription of anti-depressants.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.